Nationwide survey of the development of drug-resistance in the pediatric field: Drug sensitivity of Haemophilus influenzae in Japan

Journal of Infection and Chemotherapy

Volumn 15, Issue 6, 2009, Pages 402-409

  Sakata, Hiroshi ^a   Toyonaga, Yoshikiyo ^b   Sato, Yoshitake ^c   Hanaki, Hideaki ^d   Nonoyama, Masato ^e   Oishi, Tomohiro ^f   Sunakawa, Keisuke ^d  

^a Asahikawa Kosei Hospital   (Japan)

^b Sekishinkai Sayama Hospital   (Japan)

^c FUJI HEAVY INDUSTRIES LTD   (Japan)

^d KITASATO INSTITUTE   (Japan)

^e Ebina General Hospital   (Japan)

^f Department of Pediatrics   (Japan)

Author keywords

Drug resistance; Haemophilus influenzae; Pediatric infectious disease; Sensitivity; Surveillance

Indexed keywords

AMPICILLIN; BETA LACTAMASE; CEFDINIR; CEFPODOXIME; CEFTRIAXONE; CLARITHROMYCIN; FROPENEM; PANIPENEM; ROKITAMYCIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; HAEMOPHILUS INFLUENZAE; HEALTH SURVEY; HUMAN; JAPAN; MINIMUM INHIBITORY CONCENTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

EID: 76749152351     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-009-0729-1     Document Type: Article

References (19)

1. K. Hasegawa N. Chiba R. Kobayashi S.Y. Murayama S. Iwata K. Sunakawa, et al. 2004 Rapidly increasing prevalence of β-lactamasenonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis Antimicrob Agents Chemother 48 1509 1514 10.1128/AAC.48.5.1509-1514.2004 1:CAS:528:DC%2BD2cXjslClsrc%3D 15105098 (Pubitemid 38544352)
2. K. Hasegawa R. Kobayashi E. Takada A. Ono N. Chiba M. Morozumi, et al. 2006 High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced J Antimicrob Chemother 57 1077 1082 10.1093/jac/dkl142 1:CAS:528:DC%2BD28XmsFyktrc%3D 16617062 (Pubitemid 44644408)
3. Japanese Society of Chemotherapy. 1981 Committee for Revision of MIC Determination Method: Revision of minimal inhibitory concentration (MIC) determination method Chemotherapy 29 76 79
4. National Committee for Clinical Laboratory Standards. MIC testing supplemental tables. NCCLS Document M100-S13 (M7). Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards; 2003.
5. Clements DA. Haemophilus influenzae type b. In: Gershon AA, Hotez PJ, Katz SL, editors. Krugman's infectious diseases of children. 11th ed. Philadelphia: Mosby; 2004. p. 239-257.
6. P.T. Heath J. McVernon 2002 The UK Hib vaccine experience Arch Dis Child 86 396 399 10.1136/adc.86.6.396 1:STN:280:DC%2BD383os1Gnug%3D%3D 12023165 (Pubitemid 34596646)
7. M.R. Jacobs D. Felmingham P.C. Appelbaum R.N. Gruneberg 2003 The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J Antimicrob Chemother 52 229 246 10.1093/jac/dkg321 1:CAS:528: DC%2BD3sXmtFKrsrg%3D 12865398 (Pubitemid 36986885)
8. K.P. Heilmann C.L. Rice A.L. Miller N.J. Miller S.E. Beekmann M.A. Pfaller, et al. 2005 Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States Antimicrob Agents Chemother 49 2561 2564 10.1128/AAC.49.6.2561-2564.2005 1:CAS:528:DC%2BD2MXkvFCgt7w%3D 15917574 (Pubitemid 40734507)
9. H. Sakata 2006 Bactericidal activities of parenteral antibiotics and genotype of penicillin-binding protein in Streptococcus pneumoniae and Haemophilus influenzae isolated from children's blood J Infect Chemother 12 338 342 10.1007/s10156-006-0467-6 1:CAS:528:DC%2BD28Xht1Wgu7nO 17109098 (Pubitemid 44760514)
10. Matsumoto A, Hosoya M, Katayose M, Murai H, Kawasaki Y, Sato K, et al. Antimicrobial resistance in Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharynxi in children. Kansenshogaku Zasshi 78:482-489.
11. H. Endo Y. Kayama K. Kawamura N. Sato H. Shimoda K. Ubukata, et al. 2002 Bacterial strains isolated from upper pharynx of young children suffering from acute respiratory tract infections J J Pediatr Soc 106 472 481
12. Uno Y. Surveillance based on molecular epidemiology for Streptococcus pneumoniae isolated from the nasopharynx in pediatric patients with acute otitis media. JPN J Chemotherapy; 52:68-74.
13. Uno Y. Surveillance based on molecular epidemiology of Haemophilus influenzae isolated from the nasopharynx of pediatric patients with acute otitis media. JPN J Chemotherapy; 52:163-168.
14. M. Ito A. Shirai K. Sakunaka T. Tsukatani K. Shibuya T. Yoshizaki, et al. 2000 Rate of isolation of nasopharyngeal penicillin-resistant Streptococcus pneumoniae from 18-month-old infants Oto-Rhino-Laryngology Tokyo 43 540 546
15. M. Ito M. Furukawa 2002 Survey of the rate of isolation of Haemophilus influenzae in the general population Journal of Japan Society for Infectious Diseases in Otolaryngology 20 94 97
16. D. Felmingham R.R. Reinert Y. Hirakata A. Rodloff 2002 Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin J Antimicrob Chemother 50 SupplS1 25 37 1:CAS:528:DC%2BD38XnvFCmtrg%3D 12239226
17. D. Hoban D. Felmingham 2002 The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections J Antimicrob Chemother 50 Suppl 49 59 1:CAS:528:DC%2BD38XnvFCmtrY%3D 12239228
18. K. Ubukata N. Chiba R. Kobayashi K. Hasegawa M. Konno 2002 Surveillance based on molecular epidemiology for Haemophilus influenzae isolates between 1998 and 2000 in Japan. Results of clinical isolates of Streptococcus pneumoniae, etc., collected by the Community-Acquired Bacterial Infections Working Group Japanese Journal of Chemotherapy 50 794 804
19. K. Ubukata R. Kobayashi N. Chiba K. Hasegawa M. Konno 2003 Surveillance based on molecular epidemiology for Streptococcus pneumoniae isolates between 1998 and 2000 in Japan. Results of clinical isolates collected by the Community-Acquired Bacterial Infections Working Group JPN J Chemotherapy 51 60 70 1:CAS:528:DC%2BD3sXhslygs7g%3D